

Sylvia L Asa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1637922/publications.pdf>

Version: 2024-02-01

565
papers

38,175
citations

3531

90
h-index

4432

172
g-index

620
all docs

620
docs citations

620
times ranked

25165
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Genomic Characterization of Papillary Thyroid Carcinoma. <i>Cell</i> , 2014, 159, 676-690.	28.9	2,318
2	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	4.5	1,738
3	Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 1023.	7.1	1,192
4	The prevalence of pituitary adenomas. <i>Cancer</i> , 2004, 101, 613-619.	4.1	1,126
5	The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism. <i>JAMA Surgery</i> , 2016, 151, 959.	4.3	840
6	Pathogenetic mechanisms in thyroid follicular-cell neoplasia. <i>Nature Reviews Cancer</i> , 2006, 6, 292-306.	28.4	797
7	Induction of intestinal epithelial proliferation by glucagon-like peptide 2.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996, 93, 7911-7916.	7.1	777
8	A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. <i>Modern Pathology</i> , 2018, 31, 1770-1786.	5.5	739
9	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	4.5	717
10	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. <i>Cancer Cell</i> , 2017, 31, 181-193.	16.8	532
11	Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 14938-14943.	7.1	504
12	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. <i>Cancer Cell</i> , 2016, 29, 723-736.	16.8	482
13	Observer Variation in the Diagnosis of Follicular Variant of Papillary Thyroid Carcinoma. <i>American Journal of Surgical Pathology</i> , 2004, 28, 1336-1340.	3.7	456
14	Pituitary Lactotroph Hyperplasia and Chronic Hyperprolactinemia in Dopamine D2 Receptor-Deficient Mice. <i>Neuron</i> , 1997, 19, 103-113.	8.1	398
15	Overview of the 2022 WHO Classification of Thyroid Neoplasms. <i>Endocrine Pathology</i> , 2022, 33, 27-63.	9.0	388
16	<i>EWSR1</i> – <i>ATF1</i> fusion is a novel and consistent finding in hyalinizing clear-cell carcinoma of salivary gland. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 559-570.	2.8	339
17	Pulmonary pathology of severe acute respiratory syndrome in Toronto. <i>Modern Pathology</i> , 2005, 18, 1-10.	5.5	331
18	The pathogenesis of pituitary tumours. <i>Nature Reviews Cancer</i> , 2002, 2, 836-849.	28.4	327

#	ARTICLE	IF	CITATIONS
19	Immunohistochemical Diagnosis of Papillary Thyroid Carcinoma. <i>Modern Pathology</i> , 2001, 14, 338-342.	5.5	298
20	The Cytogenesis and Pathogenesis of Pituitary Adenomas*. <i>Endocrine Reviews</i> , 1998, 19, 798-827.	20.1	285
21	Interobserver and Intraobserver Variation Among Experts in the Diagnosis of Thyroid Follicular Lesions With Borderline Nuclear Features of Papillary Carcinoma. <i>American Journal of Clinical Pathology</i> , 2008, 130, 736-744.	0.7	280
22	Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. <i>Nature Genetics</i> , 2013, 45, 1483-1486.	21.4	275
23	A Case for Hypothalamic Acromegaly: A Clinicopathological Study of Six Patients with Hypothalamic Gangliocytomas Producing Growth Hormone-Releasing Factor*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1984, 58, 796-803.	3.6	271
24	Growth Hormone-Releasing Hormone-Producing Tumors: Clinical, Biochemical, and Morphological Manifestations*. <i>Endocrine Reviews</i> , 1988, 9, 357-373.	20.1	265
25	From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. <i>Endocrine-Related Cancer</i> , 2017, 24, C5-C8.	3.1	262
26	Distinct Multiple RET/PTC Gene Rearrangements in Multifocal Papillary Thyroid Neoplasia ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 4116-4122.	3.6	242
27	Immunomodulation by bromocriptine. <i>Immunopharmacology</i> , 1983, 6, 231-243.	2.0	236
28	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism: A Distinct Clinicopathologic Entity. <i>Annals of Internal Medicine</i> , 1981, 95, 166.	3.9	232
29	Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. <i>Endocrine Pathology</i> , 2022, 33, 115-154.	9.0	227
30	The Pathogenesis of Pituitary Tumors. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2009, 4, 97-126.	22.4	225
31	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathke's Cleft Cyst, and Arachnoid Cyst. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 3972-3982.	3.6	221
32	Non-pheochromocytoma (PCC)/paraganglioma (PGL) tumors in patients with succinate dehydrogenase-related PCC/PGL syndromes: a clinicopathological and molecular analysis. <i>European Journal of Endocrinology</i> , 2014, 170, 1-12.	3.7	219
33	RET Oncogene Activation in Papillary Thyroid Carcinoma. <i>Advances in Anatomic Pathology</i> , 2001, 8, 345-354.	4.3	205
34	Thyroid calcification and its association with thyroid carcinoma. <i>Head and Neck</i> , 2002, 24, 651-655.	2.0	204
35	The Demise of Follicular Carcinoma of the Thyroid Gland. <i>Thyroid</i> , 1994, 4, 233-236.	4.5	192
36	The Spectrum and Significance of Primary Hypophysitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1048-1053.	3.6	182

#	ARTICLE	IF	CITATIONS
37	Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 264-274.	3.6	179
38	Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. <i>Modern Pathology</i> , 2011, 24, 1545-1552.	5.5	178
39	Overview of the 2022 WHO Classification of Pituitary Tumors. <i>Endocrine Pathology</i> , 2022, 33, 6-26.	9.0	174
40	Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2187-2190.	3.6	169
41	The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas. <i>Endocrine Pathology</i> , 2015, 26, 349-355.	9.0	167
42	The Implication of Somatotroph Adenoma Phenotype to Somatostatin Analog Responsiveness in Acromegaly. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 6290-6295.	3.6	165
43	Gonadotropin Secretion in Vitro by Human Pituitary Null Cell Adenomas and Oncocytomas**. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1986, 62, 1011-1019.	3.6	162
44	“Warthin-like Tumor” of the Thyroid. <i>American Journal of Surgical Pathology</i> , 1995, 19, 810-814.	3.7	162
45	Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice ¹ . <i>Endocrinology</i> , 1999, 140, 5348-5355.	2.8	159
46	Parathyroid Hormone-Like Peptide in Normal and Neoplastic Human Endocrine Tissues*. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1990, 71, 1112-1118.	3.6	157
47	Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2002, 109, 69-78.	8.2	155
48	Hyalinizing Trabecular Tumor of the Thyroid: A Variant of Papillary Carcinoma Proved By Molecular Genetics. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1622-1626.	3.7	153
49	Fatal Severe Acute Respiratory Syndrome Is Associated with Multiorgan Involvement by Coronavirus. <i>Journal of Infectious Diseases</i> , 2005, 191, 193-197.	4.0	153
50	Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary Are Variants of Pituitary Adenoma. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1694-1699.	3.7	151
51	Familial Adenomatous Polyposis-Associated Thyroid Cancer. <i>American Journal of Pathology</i> , 1999, 154, 127-135.	3.8	150
52	Rationale and Evidence for Sunitinib in the Treatment of Malignant Paraganglioma/Pheochromocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 5-9.	3.6	150
53	Myostatin and insulin-like growth factor-I and -II expression in the muscle of rats exposed to the microgravity environment of the NeuroLab space shuttle flight. <i>Journal of Endocrinology</i> , 2000, 167, 417-428.	2.6	149
54	Prognostic Impact of Novel Molecular Subtypes of Small Intestinal Neuroendocrine Tumor. <i>Clinical Cancer Research</i> , 2016, 22, 250-258.	7.0	149

#	ARTICLE	IF	CITATIONS
55	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Human Pathology</i> , 2009, 40, 1070-1081.	2.0	147
56	Growth Enhancement in Suppressor of Cytokine Signaling 2 (SOCS-2)-Deficient Mice Is Dependent on Signal Transducer and Activator of Transcription 5b (STAT5b). <i>Molecular Endocrinology</i> , 2002, 16, 1394-1406.	3.7	145
57	Cushing's Disease Associated with an Intrasellar Gangliocytoma Producing Corticotrophin-Releasing Factor. <i>Annals of Internal Medicine</i> , 1984, 101, 789.	3.9	141
58	OVARIAN TRANSFORMING GROWTH FACTOR- β GENE EXPRESSION: IMMUNOHISTOCHEMICAL LOCALIZATION TO THE THECAINTERSTITIAL CELLS. <i>Endocrinology</i> , 1987, 121, 1577-1579.	2.8	128
59	The Melanoma-Associated Antigen A3 Mediates Fibronectin-Controlled Cancer Progression and Metastasis. <i>Cancer Research</i> , 2008, 68, 8104-8112.	0.9	127
60	Overexpression of Cyclin D1 and Underexpression of p27 Predict Lymph Node Metastases in Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1814-1818.	3.6	126
61	Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in Nonfunctioning Pituitary Adenomas: A High Throughput TMA, Immunohistochemical Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 1745-1751.	3.6	123
62	Biomarkers of aggressive pituitary adenomas. <i>Journal of Molecular Endocrinology</i> , 2012, 49, R69-R78.	2.5	123
63	The Cloning and Chromosomal Mapping of Two Novel Human Opioid-Somatostatin-like Receptor Genes, GPR7 and GPR8, Expressed in Discrete Areas of the Brain. <i>Genomics</i> , 1995, 28, 84-91.	2.9	122
64	The 2004 World Health Organization classification of pituitary tumors: What is new?. <i>Acta Neuropathologica</i> , 2006, 111, 1-7.	7.7	121
65	Myostatin Is a Skeletal Muscle Target of Growth Hormone Anabolic Action. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 5490-5496.	3.6	120
66	Overexpression of HMGA2 relates to reduction of the let-7 and its relationship to clinicopathological features in pituitary adenomas. <i>Modern Pathology</i> , 2009, 22, 431-441.	5.5	120
67	Clinicopathological Correlations in Pituitary Adenomas. <i>Brain Pathology</i> , 2012, 22, 443-453.	4.1	120
68	Epidemiology and biomarker profile of pituitary adeno-hypophysial tumors. <i>Modern Pathology</i> , 2018, 31, 900-909.	5.5	120
69	The influence of pituitary hormones on adjuvant arthritis. <i>Arthritis and Rheumatism</i> , 1984, 27, 682-688.	6.7	119
70	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1160-1166.	3.6	116
71	Fibroblast Growth Factor Receptors as Molecular Targets in Thyroid Carcinoma. <i>Endocrinology</i> , 2005, 146, 1145-1153.	2.8	115
72	Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. <i>Endocrine Pathology</i> , 2022, 33, 90-114.	9.0	115

#	ARTICLE	IF	CITATIONS
73	Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas. <i>Modern Pathology</i> , 2016, 29, 131-142.	5.5	114
74	Clinical Safety of Renaming Encapsulated Follicular Variant of Papillary Thyroid Carcinoma: Is NIFTP Truly Benign?. <i>World Journal of Surgery</i> , 2018, 42, 321-326.	1.6	114
75	Clonality of Thyroid Nodules in Sporadic Goiter. <i>Diagnostic Molecular Pathology</i> , 1995, 4, 113-121.	2.1	113
76	Application of Immunohistochemistry to Thyroid Neoplasms. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 359-372.	2.5	113
77	Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling ¹ . <i>Endocrinology</i> , 2000, 141, 752-762.	2.8	111
78	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 878-882.	3.6	111
79	Human Fetal Adenohypophysis. <i>Neuroendocrinology</i> , 1988, 48, 423-431.	2.5	109
80	Essential Requirement for <i>Pax6</i> in Control of Enteroendocrine Proglucagon Gene Transcription. <i>Molecular Endocrinology</i> , 1999, 13, 1474-1486.	3.7	105
81	Clinical outcome of anaplastic thyroid carcinoma treated with radiotherapy of once and twice daily fractionation regimens. <i>Cancer</i> , 2006, 107, 1786-1792.	4.1	105
82	The Diagnosis and Clinical Significance of Paragangliomas in Unusual Locations. <i>Journal of Clinical Medicine</i> , 2018, 7, 280.	2.4	104
83	Prevalence of Activating <i>ras</i> Mutations in Morphologically Characterized Thyroid Nodules. <i>Thyroid</i> , 1996, 6, 409-416.	4.5	103
84	Expression of Growth Factors and Growth Factor Receptors in Normal and Tumorous Human Thyroid Tissues. <i>Thyroid</i> , 1995, 5, 67-73.	4.5	102
85	Adenohypophysial Changes in Mice Transgenic for Human Growth Hormone-Releasing Factor: A Histological, Immunocytochemical, and Electron Microscopic Investigation*. <i>Endocrinology</i> , 1989, 125, 2710-2718.	2.8	101
86	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. <i>Journal of Clinical Investigation</i> , 2002, 110, 973-981.	8.2	95
87	Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 656-662.	3.6	95
88	Human Fetal Adenohypophysis. <i>Neuroendocrinology</i> , 1986, 43, 308-316.	2.5	94
89	Measures of Submaximal Aerobic Performance Evaluate and Predict Functional Response to Growth Hormone (GH) Treatment in GH-Deficient Adults ¹ . <i>Journal of Clinical Endocrinology and Metabolism</i> , 1999, 84, 4570-4577.	3.6	94
90	Controversies in Thyroid Pathology: Thyroid Capsule Invasion and Extrathyroidal Extension. <i>Annals of Surgical Oncology</i> , 2010, 17, 386-391.	1.5	94

#	ARTICLE	IF	CITATIONS
91	Intratumoral Lymphatics and Lymph Node Metastases in Papillary Thyroid Carcinoma. <i>JAMA Otolaryngology</i> , 2003, 129, 716.	1.2	93
92	Î±-Transforming Growth Factor in the Bovine Anterior Pituitary Gland: Secretion by Dispersed Cells and Immunohistochemical Localization*. <i>Endocrinology</i> , 1987, 121, 1412-1416.	2.8	92
93	Tumor-specific downregulation and methylation of the CDH13 (H-cadherin) and CDH1 (E-cadherin) genes correlate with aggressiveness of human pituitary adenomas. <i>Modern Pathology</i> , 2007, 20, 1269-1277.	5.5	91
94	The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 2165-2170.	3.6	89
95	Molecular Basis of Hurthle Cell Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 878-882.	3.6	89
96	Expression of the Apoptosis-Inducing FAS Ligand (FASL) in Human First and Third Trimester Placenta and Choriocarcinoma Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 3173-3175.	3.6	88
97	Oncogene profile of papillary thyroid carcinoma. <i>Surgery</i> , 1999, 125, 46-52.	1.9	86
98	Cyclin D1 Protein Expression Predicts Metastatic Behavior in Thyroid Papillary Microcarcinomas But Is Not Associated with Gene Amplification. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 1810-1813.	3.6	86
99	Pituitary Tumor-Derived Fibroblast Growth Factor Receptor 4 Isoform Disrupts Neural Cell-Adhesion Molecule/N-Cadherin Signaling to Diminish Cell Adhesiveness: A Mechanism Underlying Pituitary Neoplasia. <i>Molecular Endocrinology</i> , 2004, 18, 2543-2552.	3.7	86
100	Mechanisms of Disease: the pathogenesis of pituitary tumors. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2006, 2, 220-230.	2.8	85
101	Completion Thyroidectomy Versus Total Thyroidectomy: Is There a Difference in Complication Rates? An Analysis of 350 Patients. <i>Journal of the American College of Surgeons</i> , 2007, 205, 602-607.	0.5	85
102	Precursor lesions of endocrine system neoplasms. <i>Pathology</i> , 2013, 45, 316-330.	0.6	84
103	A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. <i>British Journal of Cancer</i> , 2019, 120, 1113-1119.	6.4	83
104	Practical Pituitary Pathology: What Does the Pathologist Need to Know?. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1231-1240.	2.5	82
105	Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly. <i>Acta Neuropathologica</i> , 1980, 52, 231-234.	7.7	81
106	Vitamin D Arrests Thyroid Carcinoma Cell Growth and Induces p27 Dephosphorylation and Accumulation through PTEN/Akt-Dependent and -Independent Pathways. <i>American Journal of Pathology</i> , 2002, 160, 511-519.	3.8	80
107	Gangliocytomas of the sellar region – a review. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995, 103, 129-149.	1.2	78
108	Ikars Isoforms in Human Pituitary Tumors. <i>American Journal of Pathology</i> , 2003, 163, 1177-1184.	3.8	78

#	ARTICLE	IF	CITATIONS
109	Concurrent Medullary and Papillary Carcinomas of Thyroid with Lymph Node Metastases. American Journal of Surgical Pathology, 1996, 20, 245-250.	3.7	78
110	Immunohistological Localization of Growth Hormone-Releasing Hormone in Human Tumors*. Journal of Clinical Endocrinology and Metabolism, 1985, 60, 423-427.	3.6	77
111	Gigantism Due to Pituitary Mammotroph Hyperplasia. New England Journal of Medicine, 1990, 323, 322-327.	27.0	77
112	Analysis of Hormone Secretion by Clinically Nonfunctioning Human Pituitary Adenomas Using the Reverse Hemolytic Plaque Assay*. Journal of Clinical Endocrinology and Metabolism, 1989, 68, 73-80.	3.6	76
113	Islet Cell and Extrapancreatic Expression of the LIM Domain Homeobox Gene <i>Isl-1</i> . Molecular Endocrinology, 1991, 5, 1633-1641.	3.7	76
114	An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma. American Journal of Surgical Pathology, 2016, 40, 569-576.	3.7	75
115	Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treatment Reviews, 2016, 47, 32-45.	7.7	74
116	Controversies in papillary microcarcinoma of the thyroid. Endocrine Pathology, 2003, 14, 183-191.	9.0	73
117	Utilization of ancillary studies in thyroid fine needle aspirates: A synopsis of the National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Diagnostic Cytopathology, 2008, 36, 438-441.	1.0	73
118	Pituitary-Specific Knockout of the Carney Complex Gene <i>Prkar1a</i> Leads to Pituitary Tumorigenesis. Molecular Endocrinology, 2008, 22, 380-387.	3.7	73
119	The pars tuberalis of the human pituitary. Virchows Archiv A, Pathological Anatomy and Histology, 1982, 399, 49-59.	1.3	72
120	Lipid Degeneration in Pheochromocytomas Mimicking Adrenal Cortical Tumors. American Journal of Surgical Pathology, 1987, 11, 480-486.	3.7	72
121	Limbic Seizures Alter Reproductive Function in the Female Rat. Epilepsia, 1999, 40, 1370-1377.	5.1	72
122	Cytoplasmic Expression of Fibroblast Growth Factor Receptor-4 in Human Pituitary Adenomas: Relation to Tumor Type, Size, Proliferation, and Invasiveness. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1904-1911.	3.6	72
123	Pancreatic endocrine tumors. Modern Pathology, 2011, 24, S66-S77.	5.5	72
124	Fibroblast Growth Factor 2 and Estrogen Control the Balance of Histone 3 Modifications Targeting MAGE-A3 in Pituitary Neoplasia. Clinical Cancer Research, 2008, 14, 1984-1996.	7.0	70
125	Vasoactive intestinal peptide-containing nerves in Peyer's patches. Brain, Behavior, and Immunity, 1987, 1, 148-158.	4.1	69
126	Are activating mutations of the adrenocorticotropin receptor involved in adrenal cortical neoplasia?. Life Sciences, 1995, 56, 1523-1527.	4.3	69

#	ARTICLE	IF	CITATIONS
127	Pit-1 Binding Sites at the Somatotrope-specific DNase I Hypersensitive Sites I, II of the Human Growth Hormone Locus Control Region Are Essential for in Vivo hGH-N Gene Activation. <i>Journal of Biological Chemistry</i> , 1999, 274, 35725-35733.	3.4	68
128	Epigenetic Silencing through DNA and Histone Methylation of Fibroblast Growth Factor Receptor 2 in Neoplastic Pituitary Cells. <i>American Journal of Pathology</i> , 2007, 170, 1618-1628.	3.8	68
129	A High-Throughput Proteomic Approach Provides Distinct Signatures for Thyroid Cancer Behavior. <i>Clinical Cancer Research</i> , 2011, 17, 2385-2394.	7.0	67
130	Distinct gene expression phenotypes of cells lacking Rb and Rb family members. <i>Cancer Research</i> , 2003, 63, 3716-23.	0.9	67
131	Pituitary Hormones and Contact Sensitivity in Rats. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 1983, 38, 325-330.	5.7	66
132	Loss of Membrane Localization and Aberrant Nuclear E-cadherin Expression Correlates With Invasion in Pancreatic Endocrine Tumors. <i>American Journal of Surgical Pathology</i> , 2008, 32, 413-419.	3.7	66
133	The Current Histologic Classification of Thyroid Cancer. <i>Endocrinology and Metabolism Clinics of North America</i> , 2019, 48, 1-22.	3.2	66
134	Epigenetically Controlled Fibroblast Growth Factor Receptor 2 Signaling Imposes on the RAS/BRAF/Mitogen-Activated Protein Kinase Pathway to Modulate Thyroid Cancer Progression. <i>Cancer Research</i> , 2007, 67, 5461-5470.	0.9	65
135	Oncocytes, Oxyphils, Hürthle, and Askanazy Cells: Morphological and Molecular Features Of Oncocytic Thyroid Nodules. <i>Endocrine Pathology</i> , 2010, 21, 16-24.	9.0	65
136	Diagnosis and Pathologic Characteristics of Medullary Thyroid Carcinoma—Review of Current Guidelines. <i>Current Oncology</i> , 2019, 26, 338-344.	2.2	65
137	Papillary Thyroid Carcinoma: An Overview. <i>Archives of Pathology and Laboratory Medicine</i> , 2006, 130, 1057-1062.	2.5	65
138	The MEN-1 Gene Is Rarely Down-Regulated in Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3210-3212.	3.6	64
139	A Growth Hormone Receptor Mutation Impairs Growth Hormone Autoregulation Signaling in Pituitary Tumors. <i>Cancer Research</i> , 2007, 67, 7505-7511.	0.9	64
140	Prognostic Features in Tall Cell Papillary Carcinoma and Insular Thyroid Carcinoma. <i>Laryngoscope</i> , 1997, 107, 254-259.	2.0	63
141	DNase I-hypersensitive sites I and II of the human growth hormone locus control region are a major developmental activator of somatotrope gene expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1998, 95, 10655-10660.	7.1	62
142	Evidence for Growth Hormone (GH) Autoregulation in Pituitary Somatotrophs in GH Antagonist-Transgenic Mice and GH Receptor-Deficient Mice. <i>American Journal of Pathology</i> , 2000, 156, 1009-1015.	3.8	61
143	Severe Acute Respiratory Syndrome-associated Coronavirus in Lung Tissue. <i>Emerging Infectious Diseases</i> , 2004, 10, 20-24.	4.3	61
144	The Predictive Value of CK19 and CD99 in Pancreatic Endocrine Tumors. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1588-1594.	3.7	61

#	ARTICLE	IF	CITATIONS
145	The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas. <i>Endocrine-Related Cancer</i> , 2014, 21, R331-R344.	3.1	61
146	Pituitary Mammotroph Adenomas Develop in Old Mice Transgenic for Growth Hormone-Releasing Hormone. <i>Experimental Biology and Medicine</i> , 1990, 193, 232-235.	2.4	60
147	Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. <i>Endocrine Pathology</i> , 1995, 6, 125-134.	9.0	60
148	CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. <i>Oncogene</i> , 2007, 26, 2747-2758.	5.9	60
149	The Role of Immunohistochemical Markers in the Diagnosis of Follicular-Patterned Lesions of the Thyroid. <i>Endocrine Pathology</i> , 2005, 16, 295-310.	9.0	59
150	The FGFR4-G388R Polymorphism Promotes Mitochondrial STAT3 Serine Phosphorylation to Facilitate Pituitary Growth Hormone Cell Tumorigenesis. <i>PLoS Genetics</i> , 2011, 7, e1002400.	3.5	59
151	Clinical features of silent corticotroph adenomas. <i>Acta Neurochirurgica</i> , 2012, 154, 1493-1498.	1.7	59
152	Postnatal Ablation of POMC Neurons Induces an Obese Phenotype Characterized by Decreased Food Intake and Enhanced Anxiety-Like Behavior. <i>Molecular Endocrinology</i> , 2013, 27, 1091-1102.	3.7	59
153	Primary thyroid thymoma: A distinct clinicopathologic entity. <i>Human Pathology</i> , 1988, 19, 1463-1467.	2.0	58
154	Transforming growth factor- β in normal and neoplastic human endocrine tissues. <i>Human Pathology</i> , 1992, 23, 1360-1365.	2.0	58
155	Underexpression of p27/Kip in Thyroid Papillary Microcarcinomas With Gross Metastatic Disease. <i>JAMA Otolaryngology</i> , 2002, 128, 253.	1.2	58
156	Vitamin D3 Administration Induces Nuclear p27 Accumulation, Restores Differentiation, and Reduces Tumor Burden in a Mouse Model of Metastatic Follicular Thyroid Cancer. <i>Endocrinology</i> , 2004, 145, 5840-5846.	2.8	58
157	Carney Complex with Adrenal Cortical Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E202-E206.	3.6	57
158	Biomarkers of Parathyroid Carcinoma. <i>Endocrine Pathology</i> , 2012, 23, 221-231.	9.0	57
159	Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. <i>Clinical Cancer Research</i> , 2005, 11, 1336-41.	7.0	57
160	INTRASELLAR GANGLIOCYTOMA CONTAINING GASTRIN AND GROWTH HORMONE-RELEASING HORMONE ASSOCIATED WITH A GROWTH HORMONE-SECRETING PITUITARY ADENOMA. <i>Clinical Endocrinology</i> , 1989, 30, 213-224.	2.4	56
161	Correlation of biochemical parameters with single parathyroid adenoma weight and volume. <i>Head and Neck</i> , 2002, 24, 1000-1003.	2.0	56
162	Ultrastructural features of collagen in thyroid carcinoma tissue observed by polarization second harmonic generation microscopy. <i>Biomedical Optics Express</i> , 2015, 6, 3475.	2.9	56

#	ARTICLE	IF	CITATIONS
163	Inter-Observer Variation in the Pathologic Identification of Minimal Extrathyroidal Extension in Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2016, 26, 512-517.	4.5	56
164	Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 201-213.	3.7	56
165	Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms. <i>Journal of Clinical Investigation</i> , 2002, 110, 973-981.	8.2	56
166	Analysis of ret/PTC Gene Rearrangements Refines the Fine Needle Aspiration Diagnosis of Thyroid Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 2187-2190.	3.6	56
167	Human Fetal Adenohypophysis: Morphologic and Functional Analysis in vitro. <i>Neuroendocrinology</i> , 1991, 53, 562-572.	2.5	55
168	Treatment Options for Pancreatic Neuroendocrine Tumors. <i>Cancers</i> , 2019, 11, 828.	3.7	55
169	The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. <i>Pancreas</i> , 2021, 50, 469-493.	1.1	55
170	The Endogenous Fibroblast Growth Factor-2 Antisense Gene Product Regulates Pituitary Cell Growth and Hormone Production. <i>Molecular Endocrinology</i> , 2001, 15, 589-599.	3.7	54
171	Peptide-activated double-negative T cells can prevent autoimmune type-1 diabetes development. <i>European Journal of Immunology</i> , 2007, 37, 2234-2241.	2.9	54
172	Follicular Variant Papillary Thyroid Carcinoma Arising in Struma Ovarii. <i>Endocrine Pathology</i> , 2007, 18, 182-186.	9.0	54
173	Implications of the TCGA Genomic Characterization of Papillary Thyroid Carcinoma for Thyroid Pathology: Does Follicular Variant Papillary Thyroid Carcinoma Exist?. <i>Thyroid</i> , 2015, 25, 1-2.	4.5	54
174	Somatotroph hyperplasia without pituitary adenoma associated with a long standing growth hormone-releasing hormone-producing bronchial carcinoid. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 78, 555-560.	3.6	54
175	Intrathyroidal lymphoepithelial cysts of probable branchial origin. <i>Human Pathology</i> , 1994, 25, 1238-1242.	2.0	53
176	EFFECT OF SMS 201-995, A LONG-ACTING SOMATOSTATIN ANALOGUE, ON THE SECRETION AND MORPHOLOGY OF A PITUITARY GROWTH HORMONE CELL ADENOMA. <i>Clinical Endocrinology</i> , 1987, 26, 395-405.	2.4	52
177	Pituitary cells producing more than one hormone human pituitary adenomas. <i>Trends in Endocrinology and Metabolism</i> , 1989, 1, 104-107.	7.1	52
178	Protocol for the Examination of Specimens From Patients With Pheochromocytomas and Extra-Adrenal Paragangliomas. <i>Archives of Pathology and Laboratory Medicine</i> , 2014, 138, 182-188.	2.5	52
179	Oncocytomas and null cell adenomas of the human pituitary: Morphometric and in vitro functional comparison. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1988, 413, 333-339.	1.4	51
180	Management considerations in H&N4rthle cell carcinoma. <i>Surgery</i> , 1995, 118, 711-715.	1.9	50

#	ARTICLE	IF	CITATIONS
181	Isolation of a Murine Homologue of the Drosophila neuralized Gene, a Gene Required for Axonemal Integrity in Spermatozoa and Terminal Maturation of the Mammary Gland. <i>Molecular and Cellular Biology</i> , 2001, 21, 7481-7494.	2.3	50
182	When Thyroid Carcinoma Goes Bad: A Morphological and Molecular Analysis. <i>Head and Neck Pathology</i> , 2015, 9, 16-23.	2.6	50
183	The MEN-1 Gene Is Rarely Down-Regulated in Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1998, 83, 3210-3212.	3.6	50
184	Acromegaly and Somatotroph Hyperplasia with Adenomatous Transformation Due to Pituitary Metastasis of a Growth Hormone-Releasing Hormone-Secreting Pulmonary Endocrine Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 4776-4780.	3.6	49
185	Targeting N-Cadherin through Fibroblast Growth Factor Receptor-4: Distinct Pathogenetic and Therapeutic Implications. <i>Molecular Endocrinology</i> , 2006, 20, 2965-2975.	3.7	49
186	Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital. <i>Head and Neck</i> , 2013, 35, 35-39.	2.0	49
187	Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 462, 557-563.	2.8	49
188	The Spectrum and Significance of Primary Hypophysitis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1048-1053.	3.6	49
189	H ¹ /4rthle Cell Tumors. <i>JAMA Otolaryngology</i> , 2002, 128, 237.	1.2	48
190	Pancreatic Endocrine Pathology in von Hippel-Lindau Disease: An Expanding Spectrum of Lesions. <i>Endocrine Pathology</i> , 2004, 15, 141-148.	9.0	48
191	Therapeutic implications of accurate classification of pituitary adenomas. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 158-164.	1.5	48
192	Immunohistochemical Biomarkers in Thyroid Pathology. <i>Endocrine Pathology</i> , 2018, 29, 91-112.	9.0	48
193	GATA3 immunoreactivity expands the transcription factor profile of pituitary neuroendocrine tumors. <i>Modern Pathology</i> , 2019, 32, 484-489.	5.5	48
194	Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas. <i>Laboratory Investigation</i> , 2005, 85, 464-473.	3.7	47
195	The Cancer/Testis Antigen Melanoma-Associated Antigen-A3/A6 Is a Novel Target of Fibroblast Growth Factor Receptor 2-IIIb through Histone H3 Modifications in Thyroid Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4713-4720.	7.0	47
196	Molecular determinants of pituitary cytodifferentiation. <i>Pituitary</i> , 1999, 1, 159-168.	2.9	46
197	1 α ,25-Dihydroxyvitamin D ₃ Targets PTEN-Dependent Fibronectin Expression to Restore Thyroid Cancer Cell Adhesiveness. <i>Molecular Endocrinology</i> , 2005, 19, 2349-2357.	3.7	46
198	Immunohistochemical study of p53 protein in human and animal pituitary tumors. <i>Endocrine Pathology</i> , 1993, 4, 95-99.	9.0	45

#	ARTICLE	IF	CITATIONS
199	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. <i>Molecular Endocrinology</i> , 2001, 15, 600-613.	3.7	45
200	Pituitary Tumor AP-2 β Recognizes a Cryptic Promoter in Intron 4 of Fibroblast Growth Factor Receptor 4. <i>Journal of Biological Chemistry</i> , 2003, 278, 19597-19602.	3.4	45
201	The FGFR4-G388R Single-Nucleotide Polymorphism Alters Pancreatic Neuroendocrine Tumor Progression and Response to mTOR Inhibition Therapy. <i>Cancer Research</i> , 2012, 72, 5683-5691.	0.9	45
202	The evolving diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). <i>Human Pathology</i> , 2018, 74, 1-4.	2.0	45
203	Immunohistochemical Biomarkers of Adrenal Cortical Neoplasms. <i>Endocrine Pathology</i> , 2018, 29, 137-149.	9.0	45
204	Pituitary Lactotroph Adenomas Develop after Prolonged Lactotroph Hyperplasia in Dopamine D2 Receptor-Deficient Mice. <i>Endocrinology</i> , 1999, 140, 5348-5355.	2.8	45
205	Papillary Carcinoma of Thyroid Metastatic to the Pituitary Gland. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 935-938.	2.5	45
206	Clinically Non-Functioning Human Pituitary Adenomas. <i>Canadian Journal of Neurological Sciences</i> , 1992, 19, 228-235.	0.5	44
207	Immunohistochemical localization of p53 in human thyroid neoplasms: Correlation with biological behavior. <i>Endocrine Pathology</i> , 1997, 8, 21-28.	9.0	44
208	An essential role for the hematopoietic transcription factor Ikaros in hypothalamic-pituitary-mediated somatic growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 2214-2219.	7.1	44
209	Transcript Level Modulates the Inherent Oncogenicity of RET/PTC Oncoproteins. <i>Cancer Research</i> , 2009, 69, 4861-4869.	0.9	44
210	The dangers of parathyroid biopsy. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , 2017, 46, 4.	1.9	44
211	Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. <i>Modern Pathology</i> , 2021, 34, 1634-1650.	5.5	44
212	Glucagon and Related Peptides in Fetal Rat Hypothalamus <i>in Vivo</i> and <i>in Vitro</i> *. <i>Endocrinology</i> , 1990, 126, 110-117.	2.8	43
213	Human skin expresses growth hormone but not the prolactin gene. <i>Translational Research</i> , 2000, 136, 476-481.	2.3	43
214	Distinct clonal composition of primary and metastatic adrenocorticotrophic hormone-producing pituitary carcinoma. <i>Clinical Endocrinology</i> , 2001, 55, 549-556.	2.4	43
215	An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2019, 30, 118-127.	9.0	43
216	Molecular Basis of Pituitary Development and Cytogenesis. , 2004, 32, 1-19.		42

#	ARTICLE	IF	CITATIONS
217	XB130, a Novel Adaptor Protein, Promotes Thyroid Tumor Growth. <i>American Journal of Pathology</i> , 2011, 178, 391-401.	3.8	42
218	Aggressive Pituitary Tumors or Localized Pituitary Carcinomas: Defining Pituitary Tumors. <i>Expert Review of Endocrinology and Metabolism</i> , 2016, 11, 149-162.	2.4	42
219	The Clinicopathological Spectrum of Acromegaly. <i>Journal of Clinical Medicine</i> , 2019, 8, 1962.	2.4	42
220	The c-erbB-2/ neu proto-oncogene in human pituitary tumours. <i>Clinical Endocrinology</i> , 1997, 46, 599-606.	2.4	41
221	Prediction of Malignant Behavior of Pheochromocytomas and Paragangliomas Using Immunohistochemical Techniques. <i>Endocrine Pathology</i> , 2002, 13, 149-156.	9.0	41
222	Tumor-Derived Ikaros 6 Acetylates the Bcl-XL Promoter to Up-Regulate a Survival Signal in Pituitary Cells. <i>Molecular Endocrinology</i> , 2006, 20, 2976-2986.	3.7	41
223	Deoxyribonucleic Acid Methyltransferase 3B Promotes Epigenetic Silencing through Histone 3 Chromatin Modifications in Pituitary Cells. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2008, 93, 3610-3617.	3.6	41
224	Ectopic Thyroid Tissue Within the Gall Bladder: Case Report and Brief Review of the Literature. <i>Endocrine Pathology</i> , 2010, 21, 263-265.	9.0	41
225	Immunohistochemical localization of keratin in craniopharyngiomas and squamous cell nests of the human pituitary. <i>Acta Neuropathologica</i> , 1981, 54, 257-260.	7.7	40
226	Pituitary Morphology in Anencephalic Human Fetuses. <i>Neuroendocrinology</i> , 1997, 65, 164-172.	2.5	40
227	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. <i>Molecular Endocrinology</i> , 2002, 16, 1069-1078.	3.7	40
228	Double Adenomas of the Pituitary: Transcription Factors Pit-1, T-pit, and SF-1 Identify Cytogenesis and Differentiation. <i>Endocrine Pathology</i> , 2005, 16, 187-194.	9.0	40
229	The Zinc Finger Ikaros Transcription Factor Regulates Pituitary Growth Hormone and Prolactin Gene Expression through Distinct Effects on Chromatin Accessibility. <i>Molecular Endocrinology</i> , 2005, 19, 1004-1011.	3.7	40
230	Gonadotroph Tumor Associated with Multiple Endocrine Neoplasia Type 1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 570-574.	3.6	40
231	Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. <i>Human Pathology</i> , 2007, 38, 1810-1818.	2.0	40
232	Randomized Controlled Trial of a Computerized Decision Aid on Adjuvant Radioactive Iodine Treatment for Patients With Early-Stage Papillary Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 2906-2911.	1.6	40
233	Ikaros integrates endocrine and immune system development. <i>Journal of Clinical Investigation</i> , 2005, 115, 1021-1029.	8.2	39
234	Histological classification of pituitary disease. <i>Clinics in Endocrinology and Metabolism</i> , 1983, 12, 567-596.	1.6	38

#	ARTICLE	IF	CITATIONS
235	Immunohistologic Localization of Corticotrophin-Releasing Hormone in Human Tumors. American Journal of Clinical Pathology, 1987, 87, 327-333.	0.7	38
236	Genetics and Proteomics of Pituitary Tumors. Endocrine, 2005, 28, 043-048.	2.2	38
237	Familial pheochromocytoma and renal cell carcinoma syndrome: TMEM127 as a novel candidate gene for the association. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2015, 466, 727-732.	2.8	38
238	The association of well-differentiated thyroid carcinoma with insular or anaplastic thyroid carcinoma; evidence for dedifferentiation in tumor progression. Endocrine Pathology, 1993, 4, 215-221.	9.0	37
239	Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocrine-Related Cancer, 2017, 24, L21-L25.	3.1	37
240	Pituitary acromegaly: not one disease. Endocrine-Related Cancer, 2017, 24, C1-C4.	3.1	37
241	Pancreatic endocrine tumour producing growth hormone-releasing hormone associated with multiple endocrine neoplasia type I syndrome. European Journal of Endocrinology, 1987, 115, 331-337.	3.7	36
242	Controversies in Thyroid Pathology: The Diagnosis of Follicular Neoplasms. Endocrine Pathology, 2008, 19, 156-165.	9.0	36
243	Neuroendocrine Function and Response to Stress in Mice with Complete Disruption of Glucagon-Like Peptide-1 Receptor Signaling. Endocrinology, 2000, 141, 752-762.	2.8	36
244	THE PATHOLOGY OF PITUITARY TUMORS. Endocrinology and Metabolism Clinics of North America, 1999, 28, 13-43.	3.2	35
245	A Soluble Dominant Negative Fibroblast Growth Factor Receptor 4 Isoform in Human MCF-7 Breast Cancer Cells. Biochemical and Biophysical Research Communications, 2001, 287, 60-65.	2.1	35
246	Cushing's Syndrome Due to Ectopic CRH Secretion by Adrenal Pheochromocytoma Accompanied by Renal Infarction. Experimental and Clinical Endocrinology and Diabetes, 2006, 114, 444-447.	1.2	35
247	Prognostic and Predictive Markers in Medullary Thyroid Carcinoma. Endocrine Pathology, 2012, 23, 232-242.	9.0	35
248	lkaros integrates endocrine and immune system development. Journal of Clinical Investigation, 2005, 115, 1021-1029.	8.2	35
249	Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3078-3083.	3.6	34
250	Vitamin D and Its Analog EB1089 Induce p27 Accumulation and Diminish Association of p27 with Skp2 Independent of PTEN in Pituitary Corticotroph Cells. Brain Pathology, 2002, 12, 412-419.	4.1	34
251	Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary, 2020, 23, 322-325.	2.9	34
252	Parathyroid hormone-like peptide in pancreatic endocrine carcinoma and adenocarcinoma associated with hypercalcemia. Human Pathology, 1992, 23, 884-887.	2.0	33

#	ARTICLE	IF	CITATIONS
253	Cerebral and cerebellar gangliocytomas: a morphological study of nine cases. <i>Acta Neuropathologica</i> , 1994, 88, 246-251.	7.7	33
254	An unusual association of a sellar gangliocytoma with a prolactinoma. <i>Pituitary</i> , 2008, 11, 85-87.	2.9	33
255	Protocol for the Examination of Specimens From Patients With Primary Pituitary Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 640-646.	2.5	33
256	Simian Virus 40 T Antigen-Induced Gonadotroph Adenomas: A Model of Human Null Cell Adenomas. <i>Endocrinology</i> , 1998, 139, 3342-3351.	2.8	32
257	AIP Mutations are not Identified in Patients with Sporadic Pituitary Adenomas. <i>Endocrine Pathology</i> , 2007, 18, 76-78.	9.0	32
258	Pitfalls in the Diagnosis of Follicular Epithelial Proliferations of the Thyroid. <i>Advances in Anatomic Pathology</i> , 2012, 19, 363-373.	4.3	32
259	Pathologic Reporting of Tall-Cell Variant of Papillary Thyroid Cancer: Have We Reached a Consensus?. <i>Thyroid</i> , 2017, 27, 1498-1504.	4.5	32
260	Characterization of Pancreatic Cancer Tissue Using Multiphoton Excitation Fluorescence and Polarization-Sensitive Harmonic Generation Microscopy. <i>Frontiers in Oncology</i> , 2019, 9, 272.	2.8	32
261	Pituitary, Pancreatic and Gut Neuroendocrine Defects in Protein Tyrosine Phosphatase-Sigma-Deficient Mice. <i>Molecular Endocrinology</i> , 2002, 16, 155-169.	3.7	31
262	Xanthomatous Hypophysitis Is Associated with Ruptured Rathke's Cleft Cyst. <i>Endocrine Pathology</i> , 2017, 28, 83-90.	9.0	31
263	Reversible sellar enlargement due to growth hormone-releasing hormone production by pancreatic endocrine tumors in an acromegalic patient with multiple endocrine neoplasia type I syndrome. <i>Cancer</i> , 1988, 62, 445-450.	4.1	30
264	Malignant Teratoma of the Thyroid: Aggressive Chemoradiation Therapy is Required After Surgery. <i>Thyroid</i> , 2003, 13, 401-404.	4.5	30
265	Histone-Acetylated Control of Fibroblast Growth Factor Receptor 2 Intron 2 Polymorphisms and Isoform Splicing in Breast Cancer. <i>Molecular Endocrinology</i> , 2009, 23, 1397-1405.	3.7	30
266	Development of a molecular-beacon-based multi-allelic real-time RT-PCR assay for the detection of human coronavirus causing severe acute respiratory syndrome (SARS-CoV): a general methodology for detecting rapidly mutating viruses. <i>Archives of Virology</i> , 2011, 156, 671-680.	2.1	30
267	The Role of Mediators of Cell Invasiveness, Motility, and Migration in the Pathogenesis of Silent Corticotroph Adenomas. <i>Endocrine Pathology</i> , 2013, 24, 191-198.	9.0	30
268	Rhabdoid Tumor of the Thyroid Gland: A Variant of Anaplastic Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, e55-e57.	2.5	30
269	Regulation of Peptide-YY Synthesis and Secretion in Fetal Rat Intestinal Cultures*. <i>Endocrinology</i> , 1991, 129, 3351-3358.	2.8	29
270	Ectopic ACTH Syndrome: Discrepancy between Somatostatin Receptor Status in vivo and ex vivo, and between Immunostaining and Gene Transcription for POMC and CRH. <i>Hormone Research in Paediatrics</i> , 2002, 57, 200-204.	1.8	29

#	ARTICLE	IF	CITATIONS
271	Case Report: Adrenal LH/hCG Receptor Overexpression and Gene Amplification Causing Pregnancy-Induced Cushing's Syndrome. <i>Endocrine Pathology</i> , 2009, 20, 256-261.	9.0	29
272	Hormone profiling, WHO 2010 grading, and AJCC / UICC staging in pancreatic neuroendocrine tumor behavior. <i>Cancer Medicine</i> , 2013, 2, 701-711.	2.8	29
273	Integrated Pathology Informatics Enables High-Quality Personalized and Precision Medicine: Digital Pathology and Beyond. <i>Archives of Pathology and Laboratory Medicine</i> , 2018, 142, 369-382.	2.5	29
274	Altered Expression of Fibroblast Growth Factor Receptors in Human Pituitary Adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1160-1166.	3.6	29
275	Inhibin-expressing clear cell neuroendocrine tumor of the ampulla: an unusual presentation of von Hippel-Lindau disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2013, 463, 593-597.	2.8	28
276	Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages. <i>Endocrine Pathology</i> , 2018, 29, 332-338.	9.0	28
277	Molecular interactions during pregnancy. <i>Molecular Human Reproduction</i> , 1996, 2, 457-461.	2.8	27
278	Thyroid Gland: International Case Conference. <i>Endocrine Pathology</i> , 2002, 13, 131-134.	9.0	27
279	Ikaros Modulates Cholesterol Uptake: A Link between Tumor Suppression and Differentiation. <i>Cancer Research</i> , 2008, 68, 3715-3723.	0.9	27
280	Epigenetics of pituitary tumors: Pathogenetic and therapeutic implications. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 70-76.	3.2	27
281	Reduction of GSTP1 expression by DNA methylation correlates with clinicopathological features in pituitary adenomas. <i>Modern Pathology</i> , 2008, 21, 856-865.	5.5	26
282	Epigenetic Dysregulation in Thyroid Neoplasia. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, 389-400.	3.2	26
283	Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism. <i>Endocrine Pathology</i> , 2016, 27, 25-33.	9.0	26
284	Pituitary Adenomas Presenting as Sinonasal or Nasopharyngeal Masses. <i>American Journal of Surgical Pathology</i> , 2017, 41, 525-534.	3.7	26
285	Immunohistochemical Biomarkers in Pituitary Pathology. <i>Endocrine Pathology</i> , 2018, 29, 130-136.	9.0	26
286	Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2021, 32, 169-191.	9.0	26
287	Evaluation of the WHO 2010 Grading and AJCC/UICC Staging Systems in Prognostic Behavior of Intestinal Neuroendocrine Tumors. <i>PLoS ONE</i> , 2013, 8, e61538.	2.5	26
288	Primary frozen section diagnosis by robotic microscopy and virtual slide telepathology: the University Health Network experience. <i>Seminars in Diagnostic Pathology</i> , 2009, 26, 165-176.	1.5	25

#	ARTICLE	IF	CITATIONS
289	FGFR2 Isoforms Support Epithelial–Stromal Interactions in Thyroid Cancer Progression. <i>Cancer Research</i> , 2012, 72, 2017-2027.	0.9	25
290	Minichromosome maintenance protein 7 as prognostic marker of tumor aggressiveness in pituitary adenoma patients. <i>European Journal of Endocrinology</i> , 2016, 174, 307-314.	3.7	25
291	The Clinicopathological Spectrum of Parathyroid Carcinoma. <i>Frontiers in Endocrinology</i> , 2019, 10, 731.	3.5	25
292	Plurihormonal Pituitary Tumor of Pit-1 and SF-1 Lineages, with Synchronous Collision Corticotroph Tumor: a Possible Stem Cell Phenomenon. <i>Endocrine Pathology</i> , 2019, 30, 74-80.	9.0	25
293	Cribiform-Morular Thyroid Carcinoma Is a Distinct Thyroid Malignancy of Uncertain Cytogenesis. <i>Endocrine Pathology</i> , 2021, 32, 327-335.	9.0	25
294	Expression of activin/inhibin subunit messenger ribonucleic acids by gonadotroph adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1994, 79, 1399-1403.	3.6	25
295	The Ontogeny of Pit-1 Expression in the Human Fetal Pituitary Gland. <i>Neuroendocrinology</i> , 1996, 63, 349-355.	2.5	24
296	Aldosterone-Producing Adrenal Cortical Adenoma with Oncocytic Change and Cytoplasmic Eosinophilic Globular Inclusions. <i>Endocrine Pathology</i> , 2009, 20, 182-185.	9.0	24
297	The epigenetic landscape of differentiated thyroid cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 469, 3-10.	3.2	24
298	What's new in pituitary pathology?. <i>Histopathology</i> , 2018, 72, 133-141.	2.9	24
299	A Systematic Review and Meta-Analysis of the Diagnostic Performance of BRAF V600E Immunohistochemistry in Thyroid Histopathology. <i>Endocrine Pathology</i> , 2019, 30, 201-218.	9.0	24
300	Hypothalamic Vasopressin-Producing Tumors. <i>American Journal of Surgical Pathology</i> , 2019, 43, 251-260.	3.7	24
301	Structure, Function, and Morphology in the Classification of Pituitary Neuroendocrine Tumors: the Importance of Routine Analysis of Pituitary Transcription Factors. <i>Endocrine Pathology</i> , 2020, 31, 330-336.	9.0	24
302	Decreased follistatin gene expression in gonadotroph adenomas. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996, 81, 3397-3403.	3.6	24
303	Thyroid thymoma in childhood. <i>Endocrine Pathology</i> , 1990, 1, 123-127.	9.0	23
304	Growth hormone-releasing hormone (GHRH) and GHRH receptor (GHRH-R) isoform expression in ectopic acromegaly. <i>Clinical Endocrinology</i> , 2001, 55, 135-140.	2.4	23
305	FGF Receptor Signaling at the Crossroads of Endocrine Homeostasis and Tumorigenesis. <i>Hormone and Metabolic Research</i> , 2005, 37, 355-360.	1.5	23
306	Composite Pituitary Adenoma and Craniopharyngioma?. <i>American Journal of Surgical Pathology</i> , 2008, 32, 1736-1741.	3.7	23

#	ARTICLE	IF	CITATIONS
307	CtBP1 Interacts with Ikaros and Modulates Pituitary Tumor Cell Survival and Response to Hypoxia. <i>Molecular Endocrinology</i> , 2012, 26, 447-457.	3.7	23
308	The Breast Cancer Susceptibility Gene Product Fibroblast Growth Factor Receptor 2 Serves as a Scaffold for Regulation of NF- κ B Signaling. <i>Molecular and Cellular Biology</i> , 2012, 32, 4662-4673.	2.3	23
309	Modeling complexity in pathologist workload measurement: the Automatable Activity-Based Approach to Complexity Unit Scoring (AABACUS). <i>Modern Pathology</i> , 2015, 28, 324-339.	5.5	23
310	Clinical Applications of Whole-slide Imaging in Anatomic Pathology. <i>Advances in Anatomic Pathology</i> , 2017, 24, 215-221.	4.3	23
311	Endocrine pathology: past, present and future. <i>Pathology</i> , 2018, 50, 111-118.	0.6	23
312	Ki67 Quantitative Interpretation: Insights using Image Analysis. <i>Journal of Pathology Informatics</i> , 2019, 10, 8.	1.7	23
313	Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary. <i>Virchows Archiv A, Pathological Anatomy and Histopathology</i> , 1990, 417, 361-367.	1.4	22
314	Changes in hormone production of a recurrent silent corticotroph adenoma of the pituitary: A histologic, immunohistochemical, ultrastructural, and tissue culture study. <i>Human Pathology</i> , 1991, 22, 719-721.	2.0	22
315	Medullary thyroid carcinoma metastatic to the pituitary gland: an unusual site of metastasis. <i>Annals of Diagnostic Pathology</i> , 2008, 12, 199-203.	1.3	22
316	Solitary Fibrous Tumor of the Sella Mimicking Pituitary Adenoma: An Uncommon Tumor in a Rare Location—A Case Report. <i>Endocrine Pathology</i> , 2009, 20, 56-61.	9.0	22
317	Interobserver Variability in the Histopathologic Assessment of Extrathyroidal Extension of Well Differentiated Thyroid Carcinoma Supports the New American Joint Committee on Cancer Eighth Edition Criteria for Tumor Staging. <i>Thyroid</i> , 2019, 29, 619-624.	4.5	22
318	Sellar Glomangioma. <i>Ultrastructural Pathology</i> , 1984, 7, 49-54.	0.9	21
319	Intermediate Filaments in the Human Pituitary Gland: An Immunohistochemical Study. <i>Canadian Journal of Neurological Sciences</i> , 1990, 17, 131-136.	0.5	21
320	Pituitary Adenoma with "Honeycomb Golgi" Appearance Showing a Phenotypic Change at Recurrence from Clinically Nonfunctioning to Typical Cushing Disease. <i>Endocrine Pathology</i> , 2002, 13, 125-130.	9.0	21
321	TTF-1 Expressing Sellar Neoplasm with Ependymal Rosettes and Oncocytic Change: Mixed Ependymal and Oncocytic Variant Pituitary. <i>Endocrine Pathology</i> , 2014, 25, 436-438.	9.0	21
322	Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. <i>Human Pathology</i> , 2021, 110, 83-97.	2.0	21
323	Cytokeratin profiles in pituitary neuroendocrine tumors. <i>Human Pathology</i> , 2021, 107, 87-95.	2.0	21
324	Inherited Follicular Epithelial-Derived Thyroid Carcinomas: From Molecular Biology to Histological Correlates. <i>Endocrine Pathology</i> , 2021, 32, 77-101.	9.0	21

#	ARTICLE	IF	CITATIONS
325	Composite Adenomatoid Tumor and Myelolipoma of Adrenal Gland: Report of 2 Cases. Archives of Pathology and Laboratory Medicine, 2008, 132, 265-267.	2.5	21
326	Report of a case of pheochromocytoma producing immunoreactive ACTH and beta-endorphin. Journal of Endocrinological Investigation, 1984, 7, 117-122.	3.3	20
327	Effects of growth hormone-releasing hormone (GHRH) on densely granulated somatotroph adenomas and sparsely granulated somatotroph adenomas in vitro: a morphological and functional investigation. Journal of Endocrinological Investigation, 1989, 12, 443-448.	3.3	20
328	Cytoplasmic staining oferbB-2 but not mRNA levels correlates with differentiation in human thyroid neoplasia. Clinical Endocrinology, 1998, 49, 629-637.	2.4	20
329	Chromatin remodeling and histone modifications in pituitary tumors. Molecular and Cellular Endocrinology, 2010, 326, 66-70.	3.2	20
330	The evolution of differentiated thyroid cancer. Pathology, 2017, 49, 229-237.	0.6	20
331	Sp1-Mediated Transcriptional Control of Fibroblast Growth Factor Receptor 4 in Sarcomas of Skeletal Muscle Lineage. Clinical Cancer Research, 2004, 10, 6750-6758.	7.0	19
332	Pancreatic Endocrine Tumors. Advances in Anatomic Pathology, 2004, 11, 202-210.	4.3	19
333	Ikaros Is Regulated through Multiple Histone Modifications and Deoxyribonucleic Acid Methylation in the Pituitary. Molecular Endocrinology, 2007, 21, 1205-1215.	3.7	19
334	The emerging role of the Ikaros stem cell factor in the neuroendocrine system. Journal of Molecular Endocrinology, 2008, 41, 45-51.	2.5	19
335	Intrathyroidal Parathyroid Carcinoma: An Atypical Thyroid Lesion. Frontiers in Endocrinology, 2018, 9, 641.	3.5	19
336	Characterization of pathological thyroid tissue using polarization-sensitive second harmonic generation microscopy. Laboratory Investigation, 2020, 100, 1280-1287.	3.7	19
337	Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas. American Journal of Surgical Pathology, 2021, 45, 1264-1273.	3.7	19
338	Effects of somatostatin on somatotroph adenomas of the human pituitary: An in vitro functional and morphological study. Endocrine Pathology, 1990, 1, 228-235.	9.0	18
339	Production of alpha-subunit of glycoprotein hormones by pituitary somatotroph adenomas in vitro. European Journal of Endocrinology, 1993, 129, 565-572.	3.7	18
340	<i>ref</i>/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 1306-a-1307.	3.6	18
341	Expression of prostate-specific antigen and human glandular kallikrein 2 in the thyroid gland. Clinica Chimica Acta, 2000, 300, 171-180.	1.1	18
342	Hyalinizing Trabecular Tumor of the Thyroid Gland. American Journal of Clinical Pathology, 2004, 122, 495-496.	0.7	18

#	ARTICLE	IF	CITATIONS
343	Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer. <i>Endocrine-Related Cancer</i> , 2009, 16, 455-466.	3.1	18
344	FGFR4 Polymorphic Variants Modulate Phenotypic Features of Cushing Disease. <i>Molecular Endocrinology</i> , 2014, 28, 525-533.	3.7	18
345	Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease. <i>Annals of Surgical Oncology</i> , 2019, 26, 2533-2539.	1.5	18
346	Oncocytic Change in Thyroid Pathology. <i>Frontiers in Endocrinology</i> , 2021, 12, 678119.	3.5	18
347	Osteopontin (OPN) expression in thyroid carcinoma. <i>Anticancer Research</i> , 2010, 30, 1681-8.	1.1	18
348	Pituitary corticotroph adenoma with crookeâ€™s hyalinization. <i>Endocrine Pathology</i> , 1991, 2, 111-116.	9.0	17
349	A composite somatotroph-corticotroph pituitary adenoma. <i>Endocrine Pathology</i> , 1994, 5, 240-246.	9.0	17
350	How Familial Cancer Genes and Environmentally Induced Oncogenes Have Changed the Endocrine Landscape. <i>Modern Pathology</i> , 2001, 14, 246-253.	5.5	17
351	Intracytoplasmic Inclusions (Including the So-Called "Rhabdoid" Phenotype) in Pancreatic Endocrine Tumors. <i>Endocrine Pathology</i> , 2006, 17, 75-82.	9.0	17
352	â€œNext-Generationâ€•Pathology and Laboratory Medicine. <i>Archives of Pathology and Laboratory Medicine</i> , 2011, 135, 1531-1532.	2.5	17
353	The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression. <i>Oncogene</i> , 2012, 31, 4012-4021.	5.9	17
354	Defining diagnostic tissue in the era of personalized medicine. <i>Cmaj</i> , 2013, 185, 135-139.	2.0	17
355	Tyrosine kinase receptors as molecular targets in pheochromocytomas and paragangliomas. <i>Modern Pathology</i> , 2014, 27, 1050-1062.	5.5	17
356	ret/PTC-1, -2, and -3 Oncogene Rearrangements in Human Thyroid Carcinomas: Implications for Metastatic Potential?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1997, 82, 1306-1306.	3.6	17
357	Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring. <i>Modern Pathology</i> , 2022, 35, 712-720.	5.5	17
358	Medical management of pituitary adenomas: structural and ultrastructural changes. <i>Pituitary</i> , 2002, 5, 133-139.	2.9	16
359	"Honeycomb Golgi" in Pituitary Adenomas: Not a Marker of Gonadotroph Adenomas. <i>Endocrine Pathology</i> , 2003, 14, 363-368.	9.0	16
360	Management of Lesions of the Pituitary Stalk and Hypothalamus. , 2003, 13, 38-51.		16

#	ARTICLE	IF	CITATIONS
361	Ependymoma of the pituitary fossa. <i>Journal of Neurosurgery</i> , 2006, 105, 616-620.	1.6	16
362	Mice lacking the transcription factor Ikaros display behavioral alterations of an anti-depressive phenotype. <i>Experimental Neurology</i> , 2008, 211, 107-114.	4.1	16
363	Leydig Cell Hyperplasia Due to a Testicular Embryonal Carcinoma Producing Human Chorionic Gonadotropin. <i>Andrologia</i> , 1984, 16, 146-155.	2.1	16
364	Functional Cardiac Paraganglioma Associated with a Rare SDHC Mutation. <i>Endocrine Pathology</i> , 2014, 25, 315-320.	9.0	16
365	Comprehensive characterization of a Canadian cohort of von Hippel-Lindau disease patients. <i>Clinical Genetics</i> , 2019, 96, 461-467.	2.0	16
366	Malignant Pheochromocytoma Secreting Vasoactive Intestinal Peptide and Response to Sunitinib: A Case Report and Literature Review. <i>Endocrine Practice</i> , 2014, 20, e145-e150.	2.1	15
367	Hypothalamic Endocrine Tumors: An Update. <i>Journal of Clinical Medicine</i> , 2019, 8, 1741.	2.4	15
368	Middle Ear "Adenoma" a Neuroendocrine Tumor with Predominant L Cell Differentiation. <i>Endocrine Pathology</i> , 2021, 32, 433-441.	9.0	15
369	An Update on Pituitary Neuroendocrine Tumors Leading to Acromegaly and Gigantism. <i>Journal of Clinical Medicine</i> , 2021, 10, 2254.	2.4	15
370	Genomics and Epigenomics of Pituitary Tumors: What Do Pathologists Need to Know?. <i>Endocrine Pathology</i> , 2021, 32, 3-16.	9.0	15
371	Fibroblast Growth Factor Receptor 4 Is a Target for the Zinc-Finger Transcription Factor Ikaros in the Pituitary. <i>Molecular Endocrinology</i> , 2002, 16, 1069-1078.	3.7	15
372	High-throughput drug library screening identifies colchicine as a thyroid cancer inhibitor. <i>Oncotarget</i> , 2016, 7, 19948-19959.	1.8	15
373	Pituitary Pathology in Acromegaly. <i>Endocrinology and Metabolism Clinics of North America</i> , 1992, 21, 553-574.	3.2	14
374	Distinct transcriptional control and action of fibroblast growth factor receptor 4 in differentiating skeletal muscle cells. <i>Laboratory Investigation</i> , 2004, 84, 1571-1580.	3.7	14
375	Complex Endocrinopathies in MEN-1: Diagnostic Dilemmas in Endocrine Oncology. <i>Endocrine Pathology</i> , 2007, 18, 37-41.	9.0	14
376	Development of a pituitary-specific cre line targeted to the Pit-1 lineage. <i>Genesis</i> , 2008, 46, 37-42.	1.6	14
377	Vitamin D inhibits CEACAM1 to promote insulin/IGF-I receptor signaling without compromising anti-proliferative action. <i>Laboratory Investigation</i> , 2011, 91, 147-156.	3.7	14
378	Clinical implications of accurate subtyping of pituitary adenomas: perspectives from the treating physician. <i>Turk Patoloji Dergisi</i> , 2015, 31 Suppl 1, 4-17.	0.3	14

#	ARTICLE	IF	CITATIONS
379	Establishment and Characterization of a Human Neuroendocrine Tumor Xenograft. <i>Endocrine Pathology</i> , 2016, 27, 97-103.	9.0	14
380	FGFR4 polymorphic alleles modulate mitochondrial respiration: A novel target for somatostatin analog action in pituitary tumors. <i>Oncotarget</i> , 2017, 8, 3481-3494.	1.8	14
381	Human Pituitary Corticotroph Adenomas in vitro: Morphologic and Functional Responses to Corticotropin-Releasing Hormone and Cortisol. <i>Neuroendocrinology</i> , 1990, 51, 241-248.	2.5	13
382	Plurihormonality in Pituitary Adenomas Associated with Acromegaly. <i>Endocrine Pathology</i> , 2006, 17, 291-296.	9.0	13
383	Osteopontin stimulates invasion of NCIâ€h295 cells but is not associated with survival in adrenocortical carcinoma. <i>Journal of Pathology</i> , 2009, 218, 232-240.	4.5	13
384	Metastatic Neuroendocrine Neoplasms of Unknown Primary Site. , 2021, , 357-387.		13
385	Expression of p53 in Inverted Papilloma and Malignancy Associated with Inverted Papilloma. <i>The Journal of Otolaryngology</i> , 2003, 32, 048.	0.6	13
386	Fibroblast growth factor receptor 4 (FGFR4) mediates signaling to the prolactin but not the FGFR4 promoter. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2002, 283, E490-E495.	3.5	12
387	Dopaminergic Resistant Prolactinomas in the Peripubertal Population. <i>Journal of Pediatric Endocrinology and Metabolism</i> , 2006, 19, 951-3.	0.9	12
388	Morphological distinction of cortisolâ€producing and aldosteroneâ€producing adrenal cortical adenomas: not only possible but a critical clinical responsibility. <i>Histopathology</i> , 2012, 60, 1015-1016.	2.9	12
389	Recurrent Acute-Onset Cushingâ€™s Syndrome 6 Years after Removal of a Thymic Neuroendocrine Carcinoma: From Ectopic ACTH to CRH. <i>Endocrine Pathology</i> , 2013, 24, 25-29.	9.0	12
390	Inter-Observer Variation in the Pathologic Identification of Extranodal Extension in Nodal Metastasis from Papillary Thyroid Carcinoma. <i>Thyroid</i> , 2016, 26, 816-819.	4.5	12
391	Controversies in Papillary Microcarcinoma of the Thyroid. <i>Endocrine Pathology</i> , 2003, 14, 183-192.	9.0	12
392	2020 Vision of Digital Pathology in Action. <i>Journal of Pathology Informatics</i> , 2019, 10, 27.	1.7	12
393	CEACAM1 Expression in Pancreatic Endocrine Tumors. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2009, 17, 286-293.	1.2	11
394	Molecular pathology of thyroid cancer. <i>Diagnostic Histopathology</i> , 2011, 17, 124-139.	0.4	11
395	Metabolic Glucose Status and Pituitary Pathology Portend Therapeutic Outcomes in Acromegaly. <i>PLoS ONE</i> , 2013, 8, e73543.	2.5	11
396	Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome. <i>Frontiers in Endocrinology</i> , 2021, 12, 795184.	3.5	11

#	ARTICLE	IF	CITATIONS
397	Nutrient and Peptide Regulation of Somatostatin-28 Secretion from Intestinal Cultures. <i>Endocrinology</i> , 1998, 139, 148-155.	2.8	10
398	The Mind's Eye. <i>American Journal of Clinical Pathology</i> , 2001, 116, 635-636.	0.7	10
399	Is Granulomatous Thyroiditis a Complication of Breast Implants?. <i>Endocrine Pathology</i> , 2002, 13, 239-244.	9.0	10
400	Pseudopheochromocytoma of Pregnancy. <i>Endocrine Practice</i> , 2003, 9, 376-379.	2.1	10
401	Cell-cell communication in the pituitary: orchestrator of pulsatile growth hormone secretion?. <i>Trends in Endocrinology and Metabolism</i> , 2006, 17, 299-300.	7.1	10
402	Transgenic and Knockout Mouse Models Clarify Pituitary Development, Function and Disease. <i>Brain Pathology</i> , 2001, 11, 370-383.	4.1	10
403	Myelolipoma with Adrenocortical Adenoma: An unusual Combination that can Resemble Carcinoma. <i>Endocrine Pathology</i> , 2007, 18, 103-105.	9.0	10
404	Ectopic Growth Hormone-Releasing Hormone Secretion by a Neuroendocrine Tumor Causing Acromegaly: Long-Term Follow-Up Results. <i>Endocrine Pathology</i> , 2009, 20, 127-132.	9.0	10
405	Composite Medullary and Papillary Thyroid Carcinoma In a Patient With MEN 2B. , 2009, 14, 208-213.		10
406	Villous Papillary Thyroid Carcinoma: a Variant Associated with Marfan Syndrome. <i>Endocrine Pathology</i> , 2012, 23, 254-259.	9.0	10
407	Genomic Approaches to Problems in Pituitary Neoplasia. <i>Endocrine Pathology</i> , 2014, 25, 209-213.	9.0	10
408	Endoscopic Endonasal Pituitary Surgery For Nonfunctioning Pituitary Adenomas: Long-Term Outcomes and Management of Recurrent Tumors. <i>World Neurosurgery</i> , 2021, 146, e341-e350.	1.3	10
409	Prolonged Gastrointestinal Transit in a Patient with a Glucagon-Like Peptide (GLP)-1- and -2-Producing Neuroendocrine Tumor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 3078-3083.	3.6	10
410	Left Atrial Myxoma Presenting as Migraine With Aura: A VIP-induced Syndrome?. <i>Headache</i> , 2005, 45, 251-254.	3.9	9
411	Microadenomatosis of the Pancreas in von Hippel-Lindau Disease. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1630.	3.7	9
412	Sellar Glomangioma. <i>Endocrine Pathology</i> , 2011, 22, 218-221.	9.0	9
413	The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. <i>Thyroid</i> , 2013, 23, 246-247.	4.5	9
414	Metastatic Thyroid Carcinoma to the Gastric Body. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 3958-3959.	3.6	9

#	ARTICLE	IF	CITATIONS
415	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Thyroid Carcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2017, 141, 559-563.	2.5	9
416	TFE3-Expressing Perivascular Epithelioid Cell Neoplasm (PEComa) of the Sella Turcica. <i>Endocrine Pathology</i> , 2017, 28, 22-26.	9.0	9
417	Pancreatic Neuroendocrine Tumor Producing Insulin and Vasopressin. <i>Endocrine Pathology</i> , 2018, 29, 15-20.	9.0	9
418	An Unusual Salivary Gland Tumor Mimicking Papillary Thyroid Carcinoma: Mammary Analog Secretory Carcinoma. <i>Frontiers in Endocrinology</i> , 2018, 9, 555.	3.5	9
419	Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor. <i>Genome Medicine</i> , 2020, 12, 38.	8.2	9
420	The Pangenomic Classification of Pituitary Neuroendocrine Tumors: Quality Histopathology is Required for Accurate Translational Research. <i>Endocrine Pathology</i> , 2021, 32, 415-417.	9.0	9
421	An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene. <i>Endocrinology, Diabetes and Metabolism Case Reports</i> , 2015, 2015, 140105.	0.5	9
422	The endocrine pancreas and its tumors. <i>Endocrine Pathology</i> , 1993, 4, 120-130.	9.0	8
423	Diseases of the Pituitary. <i>Neurosurgery Clinics of North America</i> , 1994, 5, 71-95.	1.7	8
424	Genetic abnormalities of the endothelium. <i>Microscopy Research and Technique</i> , 2003, 60, 30-37.	2.2	8
425	Thyroid neoplasms of follicular cell derivation: A simplified approach. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 178-185.	1.5	8
426	Tumor tissue characterization using polarization-sensitive second harmonic generation microscopy. , 2015, , .		8
427	NG2 targets tumorigenic Rb inactivation in Pit1-lineage pituitary cells. <i>Endocrine-Related Cancer</i> , 2016, 23, 445-456.	3.1	8
428	Images in Endocrine Pathology: Progressive Loss of Sustentacular Cells in a Case of Recurrent Jugulotympanic Paraganglioma over a Span of 5 years. <i>Endocrine Pathology</i> , 2020, 31, 310-314.	9.0	8
429	Stage-Sensitive Blockade of Pituitary Somatomammotrope Development by Targeted Expression of a Dominant Negative Epidermal Growth Factor Receptor in Transgenic Mice. <i>Molecular Endocrinology</i> , 2001, 15, 600-613.	3.7	8
430	Genetic Events in the Evolution of Thyroid Cancer. <i>The Journal of Otolaryngology</i> , 2002, 31, 202.	0.6	8
431	Plurihormonal pituitary tumors: Beyond the one cell-one hormone theory. <i>Endocrine Pathology</i> , 1993, 4, 1-3.	9.0	7
432	C-Cell Lesions of the Thyroid. , 1997, 2, 210-217.		7

#	ARTICLE	IF	CITATIONS
433	Granulomatous Hypophysitis with Psammoma Bodies: A Diagnostic Dilemma. <i>Endocrine Pathology</i> , 2004, 15, 359-364.	9.0	7
434	Pancreatic endocrine tumour with ductules: further observations of an unusual histological subtype. <i>Pathology</i> , 2006, 38, 5-9.	0.6	7
435	Silent Corticotroph Adenoma with Adrenal Cortical Choristoma: a Rare but Distinct Morphological Entity. <i>Endocrine Pathology</i> , 2013, 24, 162-166.	9.0	7
436	Somatostatin Receptor Ligand Therapyâ€”A Potential Therapy for Neurocytoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2395-2402.	3.6	7
437	Immunohistochemical Analysis of the Metabolic Phenotype of Adrenal Cortical Carcinoma. <i>Endocrine Pathology</i> , 2020, 31, 231-238.	9.0	7
438	Challenges in the Diagnosis of Pituitary Neuroendocrine Tumors. <i>Endocrine Pathology</i> , 2021, 32, 222-227.	9.0	7
439	Genetic and epigenetic characterization of posterior pituitary tumors. <i>Acta Neuropathologica</i> , 2021, 142, 1025-1043.	7.7	7
440	Hyalinizing Trabecular Tumor of the Thyroid Gland : Much Ado About Nothing?. <i>American Journal of Clinical Pathology</i> , 2004, 122, 495-496.	0.7	7
441	Hashimotoâ€™s thyroiditis with granulomas: A unifying immunological etiology?. <i>Endocrine Pathology</i> , 1992, 3, 52-57.	9.0	6
442	Multiple Endocrine Neoplasia Type 1. , 2014, 19, 85-89.		6
443	Significance of Crooke's Hyaline Change in Nontumorous Corticotrophs of Patients With Cushing Disease. <i>Frontiers in Endocrinology</i> , 2021, 12, 620005.	3.5	6
444	Papillary Thyroid Carcinoma and Variants. , 2010, , 91-116.		6
445	The diagnostic utility of BRAF VE1 mutation-specific immunohistochemistry in ameloblastoma. <i>Modern Pathology</i> , 2022, 35, 1570-1577.	5.5	6
446	In vitro studies of human pituitary adenomas. <i>Pathology Research and Practice</i> , 1988, 183, 561-564.	2.3	5
447	A serum-free system for primary cultures of human pituitary adenomas. <i>Endocrine Pathology</i> , 1995, 6, 289-299.	9.0	5
448	Angiopietins Are Expressed in the Normal Rat Pituitary Gland. <i>Endocrine Pathology</i> , 2005, 16, 067-074.	9.0	5
449	Anaplastic Carcinoma of the Thyroid Gland. , 2005, , 159-167.		5
450	The Pathology of Thyroid Cancer. <i>Cancer Treatment and Research</i> , 2005, 122, 23-68.	0.5	5

#	ARTICLE	IF	CITATIONS
451	Creation of a retrospective searchable neuropathologic database from print archives at Toronto's University Health Network. <i>Laboratory Investigation</i> , 2008, 88, 89-93.	3.7	5
452	Images in Endocrine Pathology: Thyrotoxicosis Associated with Destructive Thyroiditis. <i>Endocrine Pathology</i> , 2012, 23, 212-214.	9.0	5
453	XB130 Deficiency Causes Congenital Hypothyroidism in Mice due to Disorganized Apical Membrane Structure and Function of Thyrocytes. <i>Thyroid</i> , 2021, 31, 1650-1661.	4.5	5
454	The Role of the Microbiome in Gastroentero-Pancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Current Issues in Molecular Biology</i> , 2022, 44, 2015-2028.	2.4	5
455	The adrenal cortex in ectopic adrenocorticotrophic hormone syndrome: A morphological study with histology, transmission and scanning electron microscopy, flow cytometry, and image analysis. <i>Endocrine Pathology</i> , 1990, 1, 183-191.	9.0	4
456	Silent corticotroph adenoma with multiple cysts: Pars intermedia tumor?. <i>Endocrine Pathology</i> , 1992, 3, 47-51.	9.0	4
457	Granulomatous and lymphocytic thyroiditis associated with a follicular adenoma. <i>Endocrine Pathology</i> , 1992, 3, 105-109.	9.0	4
458	Is Adrenal Ovarian Thecal Metaplasia a Misnomer? Report of Three Cases of Radial Scar-Like Spindle Cell Myofibroblastic Nodule of the Adrenal Gland. <i>Endocrine Pathology</i> , 2011, 22, 222-225.	9.0	4
459	Ikaros and its interacting partner CtBP target the metalloprotease ADAMTS10 to modulate pituitary cell function. <i>Molecular and Cellular Endocrinology</i> , 2017, 439, 126-132.	3.2	4
460	Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features (NIFTP): Trading Six for a Risky Half Dozen: Reply. <i>World Journal of Surgery</i> , 2018, 42, 2279-2279.	1.6	4
461	The retrotransposon gag domain containing protein Rgag4 is an Ikaros target in the pituitary. <i>Molecular and Cellular Endocrinology</i> , 2018, 461, 188-193.	3.2	4
462	VEGFR2 is downregulated in sestamibi-negative parathyroid adenomas. <i>Head and Neck</i> , 2019, 41, 3564-3569.	2.0	4
463	Thyroid Tumor Capsular Invasion: the Bottom Line or Much Ado About Nothing?. <i>Endocrine Pathology</i> , 2020, 31, 141-142.	9.0	4
464	Follicular cells in pituitary neuroendocrine tumors. <i>Human Pathology</i> , 2021, 114, 1-8.	2.0	4
465	Nasopharyngeal neuroendocrine neoplasms: Systematic review of the literature and case presentation. <i>Journal of Neuroendocrinology</i> , 2021, 33, e13005.	2.6	4
466	NCIC CTG IND.206: A phase II umbrella trial of sunitinib (S) or temsirolimus (T) in advanced rare cancers.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2594-2594.	1.6	4
467	Issues to Consider When Implementing Digital Pathology for Primary Diagnosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1297-1297.	2.5	4
468	Cytogenesis of nonfunctioning pituitary adenomas. <i>Endocrine Pathology</i> , 1991, 2, 177-179.	9.0	3

#	ARTICLE	IF	CITATIONS
469	Immunohistochemical localization of metal binding proteins in thyroid tissues and tumors. <i>Endocrine Pathology</i> , 1992, 3, 182-187.	9.0	3
470	Pancreatic xanthomatous neuropathy associated with hyperlipidemia: A cause of abdominal pain mimicking chronic pancreatitis. <i>Human Pathology</i> , 1993, 24, 1023-1025.	2.0	3
471	HLA-D antigen expression and Langerhans' cell infiltrates in thyroid tumors. <i>Endocrine Pathology</i> , 1995, 6, 197-206.	9.0	3
472	Tumors of the ovary, maldeveloped gonads, fallopian tube and broad ligament .. <i>Clinical Endocrinology</i> , 1999, 51, 671-671.	2.4	3
473	Pancreatic Endocrine Tumors With Ductules. <i>American Journal of Surgical Pathology</i> , 2005, 29, 136-137.	3.7	3
474	Preface. <i>Endocrinology and Metabolism Clinics of North America</i> , 2008, 37, xvii-xviii.	3.2	3
475	GNAq Mutations are Not Identified in Papillary Thyroid Carcinomas and Hyperfunctioning Thyroid Nodules. <i>Endocrine Pathology</i> , 2010, 21, 250-252.	9.0	3
476	A Case Report and Review of Hyperprolactinemia that is not Prolactinoma. <i>Canadian Journal of Neurological Sciences</i> , 2011, 38, 652-655.	0.5	3
477	A History of Pituitary Pathology. <i>Endocrine Pathology</i> , 2014, 25, 6-11.	9.0	3
478	Pancreatic Neuroendocrine Tumors Producing GHRH, GH, Ghrelin, PTH, or PTHrP. , 2015, , 125-139.		3
479	Cytology and Pathology: Pitfalls and Challenges. , 2016, , 33-46.		3
480	Gonadotrope Tumors. <i>Progress in Molecular Biology and Translational Science</i> , 2016, 143, 187-210.	1.7	3
481	Letter to the Editor From Asa and Mete: "Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease" <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2649-e2649.	3.6	3
482	Pituitary carcinoma: reclassification and implications in the NET schema. <i>Endocrine Oncology</i> , 2022, 2, R14-R23.	0.4	3
483	Why? What? Where?. <i>Endocrine Pathology</i> , 1990, 1, 1-3.	9.0	2
484	Utilization of electron microscopic techniques in the in vitro study of adenohipophysial function and regulation. <i>Microscopy Research and Technique</i> , 1992, 20, 136-151.	2.2	2
485	Clinicopathological variations in cushing's syndrome. <i>Endocrine Pathology</i> , 1999, 10, 165-171.	9.0	2
486	Ductules in Pancreatic Neuroendocrine Tumors. <i>American Journal of Surgical Pathology</i> , 2004, 28, 417.	3.7	2

#	ARTICLE	IF	CITATIONS
487	Adenohypophysitis in rat pituitary allografts. <i>International Journal of Experimental Pathology</i> , 2010, 91, 445-450.	1.3	2
488	Pancreatic Struma with Papillary Thyroid Carcinoma: a Diagnostic Dilemma. <i>Endocrine Pathology</i> , 2017, 28, 91-94.	9.0	2
489	Syndrome of Inappropriate Antidiuresis in a Young Adult—Searching for the Causative Needle in the Proverbial Haystack. <i>Kidney International Reports</i> , 2020, 5, 231-234.	0.8	2
490	Images in Endocrine Pathology: High-Grade Intrathyroidal Parathyroid Carcinoma with Crooke's Hyalinization. <i>Endocrine Pathology</i> , 2020, 31, 190-194.	9.0	2
491	Hypothalamic hormone-producing tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 181, 67-74.	1.8	2
492	Pituitary. , 2009, , 1949-1983.		2
493	Neuroendocrine Neoplasms: Historical Background and Terminologies. , 2021, , 1-14.		2
494	Pituitary Neuroendocrine Neoplasms. , 2021, , 55-83.		2
495	Thyroid Neuroendocrine Neoplasms. , 2021, , 119-136.		2
496	The Next Steps for Endocrine Pathology. <i>Endocrine Pathology</i> , 2022, 33, 228-230.	9.0	2
497	Pathogenesis of multinodular goiter in elderly XB130 deficient mice: alteration of thyroperoxidase affinity with iodide and hydrogen peroxide. <i>Thyroid</i> , 2021, , .	4.5	2
498	Histological, immunohistochemical, and ultrastructural features of a rat medullary thyroid carcinoma transfected with a corticotropin-releasing hormone cDNA expression vector. <i>Endocrine Pathology</i> , 1992, 3, 39-46.	9.0	1
499	Absence of somatotrophs, lactotrophs, and thyrotrophs in the pituitary of two dwarfs with hypothyroidism: Deficiency of pituitary transcription factor-1?. <i>Endocrine Pathology</i> , 1992, 3, 93-98.	9.0	1
500	Clinical Significance of In Situ Hybridization. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1993, 101, 46-52.	1.2	1
501	The Classification of Pituitary Tumors: An Update. <i>Seminars in Neurosurgery</i> , 2001, 12, 273-288.	0.0	1
502	Growth Hormone Deficiency and Physical Function. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1839-1846.	3.6	1
503	Conclusion. <i>Modern Pathology</i> , 2001, 14, 261-262.	5.5	1
504	Parathyroid Pathology: A Practical Approach. , 2003, 8, 34-41.		1

#	ARTICLE	IF	CITATIONS
505	Familial Pituitary Adenomas and Loss of Function of AIP. <i>Advances in Anatomic Pathology</i> , 2007, 14, 58-59.	4.3	1
506	<i>Adrenal Gland.</i> , 2010, , 461-485.		1
507	The evolving landscape of endocrine pathology practice. <i>Seminars in Diagnostic Pathology</i> , 2013, 30, 157.	1.5	1
508	Editorial: The Birth of Endocrine Pathology. <i>Endocrine Pathology</i> , 2014, 25, 2-2.	9.0	1
509	Genetics and Epigenetics of Endocrine Neoplasia. <i>Molecular and Cellular Endocrinology</i> , 2014, 386, 1.	3.2	1
510	Synchronous Papillary Carcinoma of Thyroid and Lung. <i>Endocrine Pathology</i> , 2016, 27, 268-270.	9.0	1
511	Malignant Ovarian Steroid Cell Tumor Causing Severe Hyperandrogenism: Case Report And Review Of The Literature. <i>AACE Clinical Case Reports</i> , 2017, 3, e269-e274.	1.1	1
512	Perithyroidal Salivary Gland Acinic Cell Carcinoma: Morphological and Molecular Attributes of a Unique Lesion. <i>Head and Neck Pathology</i> , 2021, 15, 628-637.	2.6	1
513	Pendred Syndrome with C Cell Hyperplasia. <i>Endocrine Pathology</i> , 2021, 32, 427-428.	9.0	1
514	Targeted expression of a human pituitary tumorâ€‘derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 3303-3303.	8.2	1
515	New Diagnostic and Management Approaches in Endocrine Pathology. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 1228-1230.	2.5	1
516	<i>Paragangliomas and Pheochromocytomas.</i> , 2021, , 263-285.		1
517	Expression of nm23 antimetastatic gene product in parathyroid hyperplasia, adenoma and carcinoma. An immunohistological assessment. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2005, 26, 728-31.	1.1	1
518	<i>The pituitary gland.</i> , 0, , 2860-2898.		1
519	Lymphocytic Hypophysitis of Pregnancy Resulting in Hypopituitarism. <i>Obstetrical and Gynecological Survey</i> , 1982, 37, 175-176.	0.4	0
520	Short-term morphologic and functional effects of bromocriptine on pituitary prolactin cell adenomas in vitro. <i>Endocrine Pathology</i> , 1993, 4, 79-85.	9.0	0
521	The first four years of endocrine pathology. <i>Endocrine Pathology</i> , 1994, 5, 79-80.	9.0	0
522	Thyroid lymphomas in human thyroid tissue with autoimmune thyroid disease xenografted in severe combined immunodeficient mice. <i>Endocrine Pathology</i> , 1994, 5, 169-177.	9.0	0

#	ARTICLE	IF	CITATIONS
523	Editorial announcement. Endocrine Pathology, 1994, 5, 197-197.	9.0	0
524	Heat-shock stress-response proteins in endocrine pathology. Endocrine Pathology, 1995, 6, 3-11.	9.0	0
525	The Pathophysiology of Pituitary Tumors. Seminars in Neurosurgery, 2001, 12, 261-272.	0.0	0
526	Hypothalamic Disease. , 2004, , 678-687.		0
527	Current views on pathogenesis of pituitary tumors. Current Opinion in Endocrinology, Diabetes and Obesity, 2004, 11, 281-286.	0.6	0
528	Images in Endocrine Pathology: Lipoadenoma-like Cystic Epithelial Lesion in the Lateral Neck. Endocrine Pathology, 2011, 22, 229-231.	9.0	0
529	Mechanisms of pituitary tumorigenesis. , 0, , 652-668.		0
530	In Reply. Archives of Pathology and Laboratory Medicine, 2015, 139, 967-968.	2.5	0
531	Molecular Pathogenesis of Pituitary Tumors. , 2017, , 165-175.		0
532	Hypothalamic Disease. , 2017, , 97-106.		0
533	Pituitary Tumors; Diagnosis and Treatment. , 2018, , 257-257.		0
534	Molecular Predictors of Clinical Behavior in Pituitary Adenohypophysial Tumors. Contemporary Endocrinology, 2019, , 155-172.	0.1	0
535	Pathology of pituitary growth hormone excess. , 2021, , 17-37.		0
536	Pituitary corticotroph tumour with adrenocortical cells: A distinct clinicopathologic entity with unique morphology and methylation profile. Neuropathology and Applied Neurobiology, 2022, 48, .	3.2	0
537	Single-cell transcriptome and genome analysis: A much-needed tool for pituitary neuroendocrine tumor studies. Neuro-Oncology, 2021, 23, 1803-1804.	1.2	0
538	Adrenal Gland. , 2022, , 461-486.		0
539	Cystic Lesions of the Pituitary: Clinicopathological Features Distinguishing Craniopharyngioma, Rathke's Cleft Cyst, and Arachnoid Cyst. Obstetrical and Gynecological Survey, 2000, 55, 221-223.	0.4	0
540	FISHing in the thyroid: new gene rearrangements and new ideas about their pathophysiologic basis. Advances in Anatomic Pathology, 2001, 8, 359-360.	4.3	0

#	ARTICLE	IF	CITATIONS
541	Creation of a Retrospective Searchable Neuropathologic Database from Print Archives: The UHN Experience. <i>FASEB Journal</i> , 2007, 21, A400.	0.5	0
542	Adenohypophysitis in rat pituitary allografts.. <i>FASEB Journal</i> , 2008, 22, .	0.5	0
543	Endocrine-Immune Interactions in Pituitary Pathology. , 1994, , 243-252.		0
544	Papillary Carcinoma of the Thyroid with Stromal Lymphoid Infiltrate. <i>American Journal of Surgical Pathology</i> , 1997, 21, 738-739.	3.7	0
545	A single-arm, phase II, multicenter trial of sunitinib (SU) in locally advanced or metastatic pheochromocytoma/paraganglioma (PC/PG): Updated interim results.. <i>Journal of Clinical Oncology</i> , 2014, 32, e15621-e15621.	1.6	0
546	Pathology of Tumors of the Thyroid Gland. , 0, , 459-459.		0
547	Liver Transplantation in a Young Patient with Severe and Refractory Carcinoid Syndrome. <i>AACE Clinical Case Reports</i> , 2018, 4, e289-e293.	1.1	0
548	SUN-453 Absence of Crooke's Hyaline Changes May Predict Worse Outcomes in Patients with Cushing Disease. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	0
549	Acidophil Stem Cell Tumor, Pituitary. <i>Encyclopedia of Pathology</i> , 2020, , 1-4.	0.0	0
550	Gonadotroph Tumor. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
551	Parathyroid Hyperplasia. <i>Encyclopedia of Pathology</i> , 2020, , 1-4.	0.0	0
552	Corticotroph Tumour. <i>Encyclopedia of Pathology</i> , 2020, , 1-6.	0.0	0
553	Pituitary Carcinoma. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
554	Null Cell Tumor. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
555	Mammomatotroph Tumor. <i>Encyclopedia of Pathology</i> , 2020, , 1-3.	0.0	0
556	GATA2. <i>Encyclopedia of Pathology</i> , 2020, , 1-2.	0.0	0
557	Parathyroid Adenoma. <i>Encyclopedia of Pathology</i> , 2020, , 1-4.	0.0	0
558	C-Cell Hyperplasia. <i>Encyclopedia of Pathology</i> , 2020, , 1-4.	0.0	0

#	ARTICLE	IF	CITATIONS
559	Lactotroph Tumor. Encyclopedia of Pathology, 2020, , 1-3.	0.0	0
560	Pituitary Neuroendocrine Tumor. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
561	Medullary Thyroid Carcinoma. Encyclopedia of Pathology, 2020, , 1-5.	0.0	0
562	Pancreatic Neuroendocrine Neoplasms. , 2021, , 245-261.		0
563	Parathyroid Neuroendocrine Neoplasms. , 2021, , 137-150.		0
564	Molecular profiling confirms historical immunohistochemistry in acromegaly. Endocrine-Related Cancer, 2020, 27, L1-L2.	3.1	0
565	Oncologic Outcome Prediction in Differentiated Thyroid Carcinoma: Assumption or Improved Accuracy?. Thyroid, 0, , .	4.5	0